CDT vs. SPRY, IMNM, ABVX, ZNTL, TYRA, IRON, CNTA, ETNB, EOLS, and CVAC
Should you be buying Conduit Pharmaceuticals stock or one of its competitors? The main competitors of Conduit Pharmaceuticals include ARS Pharmaceuticals (SPRY), Immunome (IMNM), ABIVAX Société Anonyme (ABVX), Zentalis Pharmaceuticals (ZNTL), Tyra Biosciences (TYRA), Disc Medicine (IRON), Centessa Pharmaceuticals (CNTA), 89bio (ETNB), Evolus (EOLS), and CureVac (CVAC). These companies are all part of the "pharmaceutical preparations" industry.
ARS Pharmaceuticals (NASDAQ:SPRY) and Conduit Pharmaceuticals (NASDAQ:CDT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, community ranking, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.
ARS Pharmaceuticals currently has a consensus target price of $18.50, indicating a potential upside of 108.33%. Given Conduit Pharmaceuticals' higher probable upside, equities analysts clearly believe ARS Pharmaceuticals is more favorable than Conduit Pharmaceuticals.
Conduit Pharmaceuticals has lower revenue, but higher earnings than ARS Pharmaceuticals.
ARS Pharmaceuticals has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500. Comparatively, Conduit Pharmaceuticals has a beta of 2.52, meaning that its share price is 152% more volatile than the S&P 500.
ARS Pharmaceuticals' return on equity of 0.00% beat Conduit Pharmaceuticals' return on equity.
In the previous week, ARS Pharmaceuticals and ARS Pharmaceuticals both had 2 articles in the media. ARS Pharmaceuticals' average media sentiment score of 1.35 beat Conduit Pharmaceuticals' score of 0.68 indicating that Conduit Pharmaceuticals is being referred to more favorably in the news media.
ARS Pharmaceuticals received 10 more outperform votes than Conduit Pharmaceuticals when rated by MarketBeat users.
68.2% of ARS Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.3% of Conduit Pharmaceuticals shares are owned by institutional investors. 40.1% of ARS Pharmaceuticals shares are owned by company insiders. Comparatively, 23.5% of Conduit Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
ARS Pharmaceuticals beats Conduit Pharmaceuticals on 6 of the 11 factors compared between the two stocks.
Get Conduit Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CDT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CDT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Conduit Pharmaceuticals Competitors List
Related Companies and Tools
